Importantly, these alterations have therapeutic relevance: several PI3K/AKT/mTOR inhibitors have been investigated in early phase trials for gynecologic tumors, and the PI3Kα inhibitor alpelisib has shown preclinical efficacy against PIK3CA-mutant cervical carcinoma models [40]. This evidence concerns the gene AKT1 and cervical carcinoma.